Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 42CNS 37Genitourinary 33Thoracic 28Breast 28Head & Neck 19Lymphoid 18Sarcoma 17Dermatologic 10Gynecologic 8Other solid neoplasm 4Tumor-Agnostic 3Plasma cell 2Other hematologic neoplasm 2Other neoplasm 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

lutetium Lu 177 dotatate 13Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 4Octreotide 3Lutetium-177 3Ipilimumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1pasireotide 1entrectinib 1copper dotatate CU-64 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Radiotherapy × NET × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡